Skip to main content
ABIVAX logo

ABIVAX — Investor Relations & Filings

Ticker · ABVX ISIN · FR0012333284 LEI · 969500D8TMNB184OJU95 PA Manufacturing
Open in API
Filings indexed 873 across all filing types
Latest filing 2025-06-02 Interim / Quarterly Rep…
Country FR France
Listing PA ABVX

About ABIVAX

https://www.abivax.com

Abivax is a clinical-stage biotechnology company developing therapeutics for chronic inflammatory diseases by regulating the immune system. The company's scientific approach is centered on harnessing microRNA (miRNA) biology. Its lead drug candidate, obefazimod, is an investigational, once-daily, oral small molecule with a novel mechanism of action that enhances the expression of miR-124, a natural regulator of the inflammatory response. The primary development program for obefazimod focuses on ulcerative colitis, for which the company has reported positive Phase 3 clinical trial results. Abivax is also investigating the candidate for the treatment of Crohn's disease and other inflammatory conditions, while exploring follow-on compounds.

Recent filings

Filing Released Lang Actions
Etats financiers consolidés condensés intermédiaires (non audités) au 31 mars 2025
Interim / Quarterly Report Classification · 1% confidence The document is titled 'ÉTATS FINANCIERS CONSOLIDÉS CONDENSÉS INTERMÉDIAIRES (NON AUDITÉS) AU 31 MARS 2025' (Condensed Interim Consolidated Financial Statements as of March 31, 2025). It contains detailed financial statements, management discussion and analysis (Rapport d'activité), and risk factors for a period shorter than a full fiscal year. It is not an announcement of a report, but the report itself, containing substantive financial data. Therefore, it is classified as an Interim/Quarterly Report. Q1 2025
2025-06-02 French
Abivax Presents First Quarter 2025 Financial Results
Earnings Release Classification · 1% confidence The document is a press release titled 'Abivax Presents First Quarter 2025 Financial Results'. It provides a summary of key financial highlights, including income statement and balance sheet data for the quarter ended March 31, 2025. While it contains financial data, it is structured as a corporate news announcement disseminated via EQS News, rather than a full, formal interim report. According to the filing definitions, an 'Earnings Release' (ER) is the initial announcement of quarterly financial results containing key highlights, which matches this document perfectly. Q1 2025
2025-06-02 English
Abivax presente ses resultats financiers du premier trimestre 2025
Earnings Release Classification · 1% confidence The document is titled "Abivax présente ses résultats financiers du premier trimestre 2025" (Abivax presents its first quarter 2025 financial results). It contains detailed, consolidated, unaudited financial tables (Income Statement and Balance Sheet) for the period ending March 31, 2025, along with management commentary explaining the figures. This structure is characteristic of a comprehensive financial report for a period shorter than a year, which aligns with the definition of an Interim / Quarterly Report (IR). Although it is presented as a press release, the core content is the detailed financial results, not just highlights (which would be ER) or an announcement of a report's publication (which would be RPA/RNS). Since the document contains the actual financial data for the interim period, IR is the most appropriate classification. Q1 2025
2025-06-02 French
Déclaration de la personne responsable du rapport financier intermédiaire
Regulatory Filings Classification · 1% confidence The document is a formal certification statement signed by the CEO (Marc de Garidel) attesting to the accuracy of the interim financial statements and the activity report. According to the 'CERTIFICATION RULE', documents that are primarily officer certifications or attestations, even if they reference a specific report type (like an interim report), should be classified as Regulatory Filings (RNS) rather than the report itself, as they do not contain the actual financial data tables. Q1 2025
2025-06-02 French
ABIVAX: Nombre d’actions composant le capital social et nombre total de droits de vote au 30.04.25.
Declaration of Voting Results & Voting Rights Announcements Classification · 1% confidence The document is a formal announcement dated May 14, 2025, titled 'Nombre d'actions composant le capital social et nombre total de droits de vote' (Number of shares comprising the share capital and total number of voting rights). It explicitly references French regulatory articles (Article L. 233-8 II of the Commercial Code and Article 223-16 of the AMF General Regulation) and provides a table detailing the total number of shares and voting rights as of April 30, 2025. This type of mandatory disclosure regarding the total share count and voting power is a specific regulatory filing requirement, often related to capital structure changes or required periodic updates. Since it is a specific regulatory disclosure about share capital and voting rights, it fits best under the 'Share Issue/Capital Change' (SHA) category, as it directly relates to the capital structure, or potentially 'Regulatory Filings' (RNS) if SHA is too narrow. Given the specific nature of reporting the total number of shares and voting rights, SHA is the most precise fit, as it concerns the capital base.
2025-05-14 French
ABIVAX: Nombre dactions composant le capital social et nombre total de droits de vote au 30.04.25.
Declaration of Voting Results & Voting Rights Announcements Classification · 1% confidence The document is a regulatory announcement from ABIVAX, dated May 14, 2025, titled 'ABIVAX: Nombre d’actions composant le capital social et nombre total de droits de vote au 30.04.25.' It explicitly states it is 'Information réglementaire transmise par EQS Group' and provides a table detailing the 'Nombre d’actions' and 'Nombre total de droits de vote' as of April 30, 2025, referencing French commercial code and AMF regulations (Article 223-16). This type of periodic disclosure regarding the total share capital and voting rights is a standard regulatory filing requirement in France, but it does not fit neatly into the primary categories like 10-K, ER, or IR. Since it is a specific regulatory disclosure that doesn't match the other defined codes (like DVA for voting *results* or SHA for *issuance*), the most appropriate general regulatory fallback category is RNS (Regulatory Filings). The document is short and serves as a notification of this specific data point.
2025-05-14 French

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.